Rna Diagnostics' News - Two new research studies related to RDA published in leading journals, clinical collaborations expanded, new RnaDx lab in Sudbury.


Spring 2014

New research expands applications for RDA™ 

Two research studies related to Rna Diagnostic’s Rna Disruption Assay™ (RDA™), each with far reaching positive implications, have recently been published in leading scientific journals.

A paper supporting the use of RDA to assess the effectiveness of chemotherapy on breast cancer was published in Breast Cancer Research and Treatment.
The paper entitled, Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the “biological window therapy”, shows that RDA™ can measure the response of breast cancer to zoledronic acid, a novel class of anti-cancer agents.
“This research represents a major advance in our understanding of both zoledronic acid drugs in breast cancer and the capacity for zoledronic drugs to induce RNA disruption,” said Dr. Ken Pritzker, CEO of Rna Diagnostics. “The paper extends the application of RDA to one more class of anti-cancer drugs.” View abstract 

The utility of RDA in assessing the effect of chemotherapy drugs has been further illustrated in research published by Toronto biopharma company Armour Therapeutics. The study entitled, “Relaxin antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts”, was published in  Endocrine-Related Cancer.

“This study clearly shows the promise of RDA to be of diagnostic value in demonstrating response to therapy in cancers such as prostate cancer”, said Dr. Ken Pritzker. “It also provides evidence that RDA is a useful test in drug development to assess response to therapy and evidence that RDA is useful as a therapy response biomarker for hormone responsive tumours.” View abstract 

Clinical collaborations

New clinical collaborations are being pursued with the Mayo Clinic in Rochester, Minnesota  (the BEAUTY trial), John Hopkins University, Baltimore, Maryland and University of Miami, Miami, Florida. These collaborations will generate additional data to support multiple intended uses for RDA. Working with these influential groups also enhances market awareness and seeds the market for early adopter clients. 

The Montreal Jewish General trial is nearing completion. Preliminary results are expected by early fall.

The EXCITE trial is in final ethics review approval with patient accrual for the EXCITE planned at five centres in Ontario starting this summer. 

New RnaDx lab in Sudbury

Rna Diagnostics' Toronto Rna Diagnostics is installing and commissioning automated equipment at the company’s Sudbury laboratory to produce the RDA test at scale to service markets around the world.  This is a separate RnaDx facility located at the Health Sciences North (HSN) campus in Sudbury.  

Sudbury RnaDx team: Dr. Amadeo Parissenti, Baoqing Guo, Dr. Stacey Santi, Rashmi Narendrula

Upcoming Events

May 22
RnaDx is hosting a meeting of breast cancer experts from across the UK in London, England. 

May 30 - June 3
We will be attending the Annual Meeting of the American Society of Clinical Oncology, in Chicago, Illinois

Management Team

Ken Pritzker, MD, FRCPC
President & CEO

Amadeo Parissenti, PhD
Chief Scientific Officer

John Connolly, MBA
VP Corporate Development

John Jordan, MBA, CPA, CMA
Chief Financial Officer

Laura Pritzker, PhD
Principal Scientist

Clinical Advisory Board

Maureen E. Trudeau, MA, MD, FRCPC, Toronto, Canada

Gunter von Minckwitz, MD, PhD, Frankfurt, Germany

Michael Untch, MD, PhD, Berlin, Germany

Harry D. Bear, MD, PhD, Richmond, VA, USA

Rna Diagnostics Inc. is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management.

Our mailing address is:
Rna Diagnostics Inc.
MaRS Centre, Heritage Building, 101 College Street, Suite HL20-4, Toronto, ON, Canada
Toronto, ON M5G 1L7

Add us to your address book
For more information contact:
John Connolly
VP Corporate Development